EFM
E Fund Management Portfolio holdings
AUM
$2.1B
This Quarter Return
+14.76%
1 Year Return
+23.31%
3 Year Return
+155.42%
5 Year Return
–
10 Year Return
–
AUM
$2.1B
AUM Growth
+$2.1B
(+0.21%)
Cap. Flow
-$186M
Cap. Flow
% of AUM
-8.85%
Top 10 Holdings %
Top 10 Hldgs %
51.83%
Holding
429
New
31
Increased
85
Reduced
265
Closed
35
Top Buys
| 1 |
abrdn Physical Gold Shares ETF
SGOL
|
$20M |
| 2 |
iShares Gold Trust
IAU
|
$19.8M |
| 3 |
SPDR Gold MiniShares Trust
GLDM
|
$19.6M |
| 4 |
SPDR Gold Trust
GLD
|
$19.6M |
| 5 |
Invesco DB Oil Fund
DBO
|
$11M |
Top Sells
| 1 |
KE Holdings
BEKE
|
$70.4M |
| 2 |
Futu Holdings
FUTU
|
$37.4M |
| 3 |
Apple
AAPL
|
$18.8M |
| 4 |
Microsoft
MSFT
|
$13.6M |
| 5 |
Applied Materials
AMAT
|
$11.3M |
Sector Composition
| 1 | Technology | 43.87% |
| 2 | Consumer Discretionary | 23.94% |
| 3 | Communication Services | 11.36% |
| 4 | Healthcare | 5.11% |
| 5 | Financials | 3.75% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
326
Amicus Therapeutics
FOLD
$2.34B
| $265K | 0.01% |
46,326
+22,610
| +95% | +$130K |
|
327
American Tower
AMT
$95.5B
| $260K | 0.01% |
1,177
-412
| -26% | -$91.1K |
|
328
Southern Company
SO
$102B
| $258K | 0.01% |
2,812
-5
| -0.2% | -$459 |
|
329
IDEAYA Biosciences
IDYA
$2.15B
| $257K | 0.01% |
12,225
+881
| +8% | +$18.5K |
|
330
Teradyne
TER
$18.8B
| $257K | 0.01% |
2,855
-650
| -19% | -$58.4K |
|
331
Altria Group
MO
$113B
| $255K | 0.01% |
4,350
-8
| -0.2% | -$469 |
|
332
CME Group
CME
$96B
| $255K | 0.01% |
925
-2
| -0.2% | -$551 |
|
333
Lockheed Martin
LMT
$106B
| $251K | 0.01% |
542
| – | – |
|
334
Prologis
PLD
$106B
| $250K | 0.01% |
2,379
-2
| -0.1% | -$210 |
|
|
JNPR
335
DELISTED
Juniper Networks
JNPR
| $250K | 0.01% |
6,253
-450
| -7% | -$18K |
|
336
Arrowhead Research
ARWR
$3.05B
| $250K | 0.01% |
15,801
-2,216
| -12% | -$35K |
|
337
Trane Technologies
TT
$92.5B
| $247K | 0.01% |
+565
| New | +$247K |
|
338
Fiserv
FI
$75.1B
| $247K | 0.01% |
1,433
-30
| -2% | -$5.17K |
|
339
Las Vegas Sands
LVS
$39.6B
| $243K | 0.01% |
5,595
| – | – |
|
340
Arcutis Biotherapeutics
ARQT
$1.86B
| $241K | 0.01% |
17,184
+2,197
| +15% | +$30.8K |
|
341
Welltower
WELL
$113B
| $236K | 0.01% |
1,535
-55
| -3% | -$8.46K |
|
|
GRAL
342
GRAIL, Inc. Common Stock
GRAL
$1.18B
| $235K | 0.01% |
+4,569
| New | +$235K |
|
343
KKR & Co
KKR
$124B
| $235K | 0.01% |
1,764
-107
| -6% | -$14.2K |
|
344
Beam Therapeutics
BEAM
$1.66B
| $233K | 0.01% |
13,675
+2,472
| +22% | +$42K |
|
345
CG Oncology
CGON
$2.04B
| $232K | 0.01% |
+8,932
| New | +$232K |
|
346
Catalyst Pharmaceutical
CPRX
$2.52B
| $231K | 0.01% |
10,656
+871
| +9% | +$18.9K |
|
347
Duke Energy
DUK
$95.3B
| $231K | 0.01% |
1,954
-496
| -20% | -$58.5K |
|
348
Vericel Corp
VCEL
$1.83B
| $225K | 0.01% |
+5,287
| New | +$225K |
|
349
Parker-Hannifin
PH
$96.2B
| $225K | 0.01% |
322
-14
| -4% | -$9.78K |
|
350
TransDigm Group
TDG
$78.8B
| $222K | 0.01% |
146
| – | – |
|